The Journal of Headache and Pain is the official journal of the European Headache Federation and Lifting the Burden.
Articles
Page 3 of 62
-
Citation: The Journal of Headache and Pain 2022 23:94
-
Long COVID headache
Headache is among the most frequent symptoms persisting or newly developing after coronavirus disease 2019 (COVID-19) as part of the so-called long COVID syndrome. The knowledge on long COVID headache is still...
Citation: The Journal of Headache and Pain 2022 23:93 -
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients
There have been a few studies regarding the pre-attack symptoms (PAS) and pre-episode symptoms (PES) of cluster headache (CH), but none have been conducted in the Chinese population. The purpose of this study ...
Citation: The Journal of Headache and Pain 2022 23:92 -
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication...
Citation: The Journal of Headache and Pain 2022 23:91 -
Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials. We repor...
Citation: The Journal of Headache and Pain 2022 23:90 -
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients
The aim of the study was to investigate whether MwoA and MwA are different manifestations of a single disease, distinct clinical entities, or located at two poles of a spectrum.
Citation: The Journal of Headache and Pain 2022 23:89 -
Association between migraine and cognitive impairment
Previous studies revealed inconsistent results regarding association between migraine and cognitive impairment. In addition, previous studies found inconsistent results regarding the association between migrai...
Citation: The Journal of Headache and Pain 2022 23:88 -
Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
The onset and duration of spontaneous migraine attacks are most often difficult to predict which, in turn, makes it challenging to study the neurobiologic underpinnings of the disease in a controlled experimen...
Citation: The Journal of Headache and Pain 2022 23:87 -
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre.
Citation: The Journal of Headache and Pain 2022 23:86 -
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study
Headache attributed to intracranial endovascular procedures is described in the ICHD-3. Our aim was to study the frequency and characteristics of headache specifically related to thrombectomy in patients with ...
Citation: The Journal of Headache and Pain 2022 23:85 -
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey
Large numbers of people with headache who would benefit are not reached by headache services. Among the causes are poor or disorganized provision of headache services, but reluctance to seek healthcare has fre...
Citation: The Journal of Headache and Pain 2022 23:84 -
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study
The pathogenesis of migraine chronification remains unclear. Functional and structural magnetic resonance imaging studies have shown impaired functional and structural alterations in the brains of patients wit...
Citation: The Journal of Headache and Pain 2022 23:83 -
Correction: The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
Citation: The Journal of Headache and Pain 2022 23:82 -
Interictal osmophobia is associated with longer migraine disease duration
Sensitization to sensory stimuli is an essential feature of migraine attacks. The relationship between the clinical course of migraine and increased sensitivity to olfactory stimuli has been little studied so ...
Citation: The Journal of Headache and Pain 2022 23:81 -
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks
Several functional neuroimaging studies on healthy controls and patients with migraine with aura have shown that the activation of functional networks during visual stimulation is not restricted to the striate...
Citation: The Journal of Headache and Pain 2022 23:80 -
Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine
Targeting fatty acid amide hydrolase (FAAH) is a promising therapeutic strategy to combat certain forms of pain, including migraine headache. FAAH inhibitors, such as the O-biphenyl-3-yl carbamate URB597, have be...
Citation: The Journal of Headache and Pain 2022 23:79 -
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study
Migraine represents a serious burden for national health systems. However, preventive treatment is not optimally applied to reduce the severity and frequency of headache attacks and the related expenses. Our a...
Citation: The Journal of Headache and Pain 2022 23:78 -
Burden of tension-type headache in the Middle East and North Africa region, 1990-2019
Tension-type headache (TTH) is the most prevalent neurological disorder. As there is a gap in the literature regarding the disease burden attributable to TTH in the Middle East and North Africa (MENA) region, ...
Citation: The Journal of Headache and Pain 2022 23:77 -
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed to explore the relative efficacy of lasmid...
Citation: The Journal of Headache and Pain 2022 23:76 -
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine
Migraine is the second most common form of headache disorder and the second leading cause of disability worldwide. Cognitive symptoms ranked second resulting in migraine-related disability, after pain. P2X7 re...
Citation: The Journal of Headache and Pain 2022 23:75 -
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
Although good treatment options exist for many headache disorders, not all patients benefit and disability continues to be large. To design strategies for improving headache care, real-world data observing sta...
Citation: The Journal of Headache and Pain 2022 23:74 -
Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats
Growing evidence supports the important role of persistent sodium currents (INaP) in the neuronal excitability of various central neurons. However, the role of tetrodotoxin-resistant (TTX-R) Na+ channel-mediated ...
Citation: The Journal of Headache and Pain 2022 23:73 -
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI
Nucleus accumbens (NAcc) played an important role in pain mediation, and presents changes of neuronal plasticity and functional connectivity. However, less is known about altered perfusion of NAcc in chronic m...
Citation: The Journal of Headache and Pain 2022 23:72 -
Repeated inflammatory dural stimulation-induced cephalic allodynia causes alteration of gut microbial composition in rats
Gut microbial dysbiosis and gut-brain axis dysfunction have been implicated in the pathophysiology of migraine. However, it is unclear whether migraine-related cephalic allodynia could induce the alteration of...
Citation: The Journal of Headache and Pain 2022 23:71 -
A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan
Migraine is a chronic disease characterized by episodic headache attacks. No recent studies have, however been conducted on the epidemiology of migraine or the treatment landscape in Japan. This study was cond...
Citation: The Journal of Headache and Pain 2022 23:70 -
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
Clinical trials have demonstrated galcanezumab as safe and effective in migraine prevention. However, real-life data are still lacking and overlook the impact of galcanezumab on those different migraine facets...
Citation: The Journal of Headache and Pain 2022 23:69 -
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine
An increasing number of studies have suggested that the important role of vasoactive peptides, such as pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) and calcitonin gene-related peptide (CGRP...
Citation: The Journal of Headache and Pain 2022 23:68 -
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized contr...
Citation: The Journal of Headache and Pain 2022 23:67 -
Narrative-based medicine in headache disorders
In this editorial we aim to provide an overview of Narrative-based Medicine (NBM) and highlight what it may offer to the care of individuals with headache disorders.
Citation: The Journal of Headache and Pain 2022 23:66 -
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
The debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on p...
Citation: The Journal of Headache and Pain 2022 23:65 -
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Citation: The Journal of Headache and Pain 2022 23:64 -
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis
Initial evidence have shown the short-term efficacy of sTMS in the acute and preventive treatment of migraine. It is unknown whether this treatment approach in the long-term is effective and well tolerated in ...
Citation: The Journal of Headache and Pain 2022 23:63 -
Effects of a history of headache and migraine treatment on baseline neurocognitive function in young athletes
Despite the prevalence of concussions in young athletes, the impact of headaches on neurocognitive function at baseline is poorly understood. We analyze the effects of a history of headache treatment on baseli...
Citation: The Journal of Headache and Pain 2022 23:62 -
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy and sa...
Citation: The Journal of Headache and Pain 2022 23:61 -
Imaging the inflammatory phenotype in migraine
Several preclinical and clinical lines of evidence suggest a role of neuroinflammation in migraine. Neuroimaging offers the possibility to investigate and localize neuroinflammation in vivo in patients with migra...
Citation: The Journal of Headache and Pain 2022 23:60 -
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor
The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates...
Citation: The Journal of Headache and Pain 2022 23:59 -
The economic and personal burden of cluster headache: a controlled cross-sectional study
Cluster headache is a less-prevalent primary headache disorder but is overrepresented with regards to use of health care and social services. More insight into the socioeconomic impact is required.
Citation: The Journal of Headache and Pain 2022 23:58 -
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
Citation: The Journal of Headache and Pain 2022 23:57 -
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy a...
Citation: The Journal of Headache and Pain 2022 23:56 -
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerabil...
Citation: The Journal of Headache and Pain 2022 23:55 -
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States
Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patient...
Citation: The Journal of Headache and Pain 2022 23:54 -
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key ro...
Citation: The Journal of Headache and Pain 2022 23:53 -
Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
The discovery of the prominent action of Calcitonin Gene Related Peptide –CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment. However, how the block of nociceptive affe...
Citation: The Journal of Headache and Pain 2022 23:52 -
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Citation: The Journal of Headache and Pain 2022 23:51 -
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inade...
Citation: The Journal of Headache and Pain 2022 23:50 -
The Global Campaign turns 18: a brief review of its activities and achievements
The Global Campaign against Headache, as a collaborative activity with the World Health Organization (WHO), was formally launched in Copenhagen in March 2004. In the month it turns 18, we review its activities...
Citation: The Journal of Headache and Pain 2022 23:49 -
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
Eptinezumab 100 mg and 300 mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1‒12. The objective of this analysis was to...
Citation: The Journal of Headache and Pain 2022 23:48 -
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates
According to the Global Burden of Disease (GBD) study, headache disorders are among the most prevalent and disabling conditions worldwide. GBD builds on epidemiological studies (published and unpublished) whic...
Citation: The Journal of Headache and Pain 2022 23:34 -
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of mig...
Citation: The Journal of Headache and Pain 2022 23:47 -
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explor...
Citation: The Journal of Headache and Pain 2022 23:46
Official journal of
Annual Journal Metrics
-
Citation Impact
8.588 - 2-year Impact Factor (2021)
7.087 - 5-year Impact Factor (2021)
1.854 - Source Normalized Impact per Paper (SNIP)
1.559 - SCImago Journal Rank (SJR)Speed
31 days to first decision for all manuscripts (Median)
63 days to first decision for reviewed manuscripts only (Median)Usage
1,531,418 Downloads
3,326 Altmetric mentions (2021)
- ISSN: 1129-2377 (electronic)
- ISSN: 1129-2369 (print)
Related reading
- Clinical Scales for Headache Disorders
- Headache Disorders in Pandemic Conditions
- Non-Migraine Primary Headaches in Medicine
- Migraine in Medicine
- Novel Synthetic Drugs in Migraine
- Monoclonal Antibodies in Headache
- Neurophysiology of the Migraine Brain
- Societal Impact of Headache
- Neuromodulation in Headache and Facial Pain Management
- Cluster Headache and other Trigeminal Autonomic Cephalgias
- Peripheral Interventional Management in Headache
- Placebos and Nocebos in Headaches
- Gender and Migraine
- Headache and Comorbidities in Childhood and Adolescence
- Comorbidities in Headache Disorders
- Pharmacological Management of Headaches
- Pathophysiology of Headaches